Articles by: TOM WINNIFRITH AND STEVE MOORE

EPIC AAZ
views

Anglo Asian Mining – Q1 update, additional production on the way - BUY

Anglo Asian Mining (AAZ) has announced it “is pleased to provide a production, sales and operations review for its Gedabek contract area in western Azerbaijan, for the three months to 31 March 2022”. So, what of the shares responding slightly higher to 95p?

  • By Tom Winnifrith and Steve Moore
  • 2022-04-18 18:18:54
EPIC FXPO
views

Ferrexpo – continuing production and sales despite its operations being in Ukraine

Iron-ore pellets producer, Ferrexpo (FXPO), has announced - despite operational constraints following Russia's invasion of Ukraine - “production of 2.7 million tonnes in the first quarter of 2022, representing a figure in line with the same period in 2021, and 11% below the previous quarter… Sales in 1Q 2022 of 2.6 million tonnes… net cash position of approximately US$159 million”.

  • By Tom Winnifrith and Steve Moore
  • 2022-04-16 16:29:30
EPIC AEXG
views

AEX Gold – Nalunaq exploration drilling results suggest very real upside potential: BUY

AEX Gold (AEXG) has announced exploration drilling results from its Nalunaq project, which, it emphasises, verify that the Valley Block, unrecognised by previous operators, is a new high-grade zone and supports its 'Dolerite Dyke Model'. This, it says, has been used to predict the location and extent of five new high-grade zones.

  • By Tom Winnifrith and Steve Moore
  • 2022-04-09 19:18:30
EPIC SMDS
views

DS Smith – Q3 trading statement, recovery Buy

Packaging company DS Smith (SMDS) has announced a trading statement including the headline “Continued momentum; trading in line with management expectations”. What does that mean relative to a current 307p share price?

  • By Tom Winnifrith and Steve Moore
  • 2022-03-20 18:09:40
EPIC OPTI
views

OptiBiotix Health – intention to list its ProBiotix Health business on AQSE, Strong Buy…

OptiBiotix Health (OPTI) has announced that it intends to seek admission of its ProBiotix Health business onto the AQSE Growth Market with an associated fund raise of approximately £2.5 million at an indicative premoney valuation of £22.5 million and a distribution in specie. With, at a 35.5p share price, OptiBiotix as a whole currently capitalised at £31.3 million, is this good news? You bet!

  • By Tom Winnifrith and Steve Moore
  • 2022-03-19 09:27:11
Page 2 of 4 (37 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments